BIOLOGY.DIGITAL
Latent Labs Emerges to Build Programmable De Novo Protein Design Foundation Models

Image: FierceBiotech

Launch

Latent Labs Emerges to Build Programmable De Novo Protein Design Foundation Models

November 14, 2026 • Source: FierceBiotech

Founded by former DeepMind AlphaFold2 co-lead Simon Kohl, Latent Labs announced its generative biology platform focused on zero-shot de novo protein binders and therapeutic enzymes.

**Executive Summary (2026-11-14):** Founded by former DeepMind AlphaFold2 co-lead Simon Kohl, Latent Labs announced its generative biology platform focused on zero-shot de novo protein binders and therapeutic enzymes. Source: FierceBiotech.

Technical Architecture & R&D Impact

The platform aims to eliminate iterative wet-lab affinity maturation by directly generating atomically accurate protein-protein interaction interfaces in silico.

Enterprise Biopharma Procurement Takeaways

For computational biology leads, medicinal chemists, and R&D IT architects, this milestone underscores the rapid convergence of wet-lab experimental validation and scalable cloud foundation models during H2 2026. Teams evaluating vendors in the Launch category should benchmark API reproducibility, GxP audit readiness, and zero-data-retention VPC deployment terms.

Related Products

Published November 14, 2026

More News

Last updated: November 14, 2026

Ask AI